ATE352558T1 - Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren - Google Patents

Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren

Info

Publication number
ATE352558T1
ATE352558T1 AT98945222T AT98945222T ATE352558T1 AT E352558 T1 ATE352558 T1 AT E352558T1 AT 98945222 T AT98945222 T AT 98945222T AT 98945222 T AT98945222 T AT 98945222T AT E352558 T1 ATE352558 T1 AT E352558T1
Authority
AT
Austria
Prior art keywords
ttc
tetanus toxin
transsynatically
hybdrid
migrant
Prior art date
Application number
AT98945222T
Other languages
English (en)
Inventor
Laurent Coen
Pinzolas Rosario Osta
Philippe Brulet
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE352558T1 publication Critical patent/ATE352558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98945222T 1997-08-14 1998-08-12 Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren ATE352558T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5561597P 1997-08-14 1997-08-14
US6523697P 1997-11-13 1997-11-13

Publications (1)

Publication Number Publication Date
ATE352558T1 true ATE352558T1 (de) 2007-02-15

Family

ID=26734425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945222T ATE352558T1 (de) 1997-08-14 1998-08-12 Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren

Country Status (9)

Country Link
US (4) US7435792B2 (de)
EP (2) EP1049712B1 (de)
AT (1) ATE352558T1 (de)
CY (1) CY1106504T1 (de)
DE (1) DE69836982T2 (de)
DK (1) DK1049712T3 (de)
ES (1) ES2281135T3 (de)
PT (1) PT1049712E (de)
WO (1) WO1999009057A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087171A (en) * 1993-12-17 2000-07-11 Spinal Cord Society Method for inducing DNA synthesis in neurons
US7923015B2 (en) 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
ATE352558T1 (de) * 1997-08-14 2007-02-15 Pasteur Institut Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
PT1234043E (pt) * 1999-12-02 2004-07-30 Health Prot Agency Construcoes para a entrega de agentes terapeuticos a celulas neuronais
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20080233049A1 (en) * 2004-06-23 2008-09-25 Ian Andrew Ferguson Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US20080044348A1 (en) * 2006-06-30 2008-02-21 Gelovani Juri G Tetanus toxin fragment C based imaging agents and methods, and confocal microscopy dataset processes
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
ES2332628B1 (es) * 2007-10-05 2011-01-24 Universidad De Zaragoza Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.
US8173768B2 (en) * 2009-07-13 2012-05-08 Centre National De La Recherche Scientifique Peptides having antimicrobial and neurotrophic activity and uses thereof
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2569018A4 (de) 2010-05-14 2013-12-04 Philadelphia Children Hospital Humanisiertes ttc und verfahren zu seiner verwendung
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3164149A1 (de) 2014-07-02 2017-05-10 Spherium Biomed S.L. Verfahren zur erhöhung der muskelmasse mit nicht toxischem tetanus-toxin-c-fragment (ttc)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470773B1 (de) 1979-11-28 1983-01-28 Pasteur Institut
CA1178949A (en) 1979-11-28 1984-12-04 Bernard Bizzini Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
US4594336A (en) * 1982-09-28 1986-06-10 Institut Pasteur Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US5004683A (en) * 1986-07-31 1991-04-02 The Research Foundation Of State University Of New York Means for detecting and analyzing neuroanatomy
US5728383A (en) 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー．ヴイ． ワクチン組成物
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5580839A (en) * 1994-09-30 1996-12-03 University Of Kentucky Research Foundation Binary ferrihydrite catalysts
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5780024A (en) * 1995-06-23 1998-07-14 The General Hospital Corp. Superoxide dismutase/tetanus toxin fragment C hybrid protein
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
US5738383A (en) * 1996-11-20 1998-04-14 Kobel, Inc. Label assembly with patterned adhesive bands
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
ATE352558T1 (de) * 1997-08-14 2007-02-15 Pasteur Institut Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20030031702A1 (en) * 2001-07-27 2003-02-13 Mazur Leonard L. Safer teratogenic pharmaceuticals
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses

Also Published As

Publication number Publication date
DK1049712T3 (da) 2007-05-29
US7435792B2 (en) 2008-10-14
US20100239534A1 (en) 2010-09-23
EP1681300A1 (de) 2006-07-19
DE69836982D1 (de) 2007-03-15
ES2281135T3 (es) 2007-09-16
US20110002914A1 (en) 2011-01-06
US20030004121A1 (en) 2003-01-02
EP1049712B1 (de) 2007-01-24
WO1999009057A3 (en) 1999-07-08
WO1999009057A2 (en) 1999-02-25
CY1106504T1 (el) 2012-01-25
EP1049712A2 (de) 2000-11-08
PT1049712E (pt) 2007-04-30
DE69836982T2 (de) 2007-10-31
US20090226468A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
DE69836982D1 (de) Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
WO1993023434A3 (en) Bpi-immunoglobulin fusion proteins
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
DE69521331D1 (de) Nukleinsäure-einbringungssystem
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE318902T1 (de) Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
IL123404A (en) Antisecretory factor peptides regulating pathological permeability changes
ATE271603T1 (de) Identifizierungsverfahren für substanzen die an das pyk2 polypeptid binden
DE60008915D1 (de) Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
BR0205083A (pt) Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
ATE133993T1 (de) Protein-antikrebsmittel
WO1997020579A3 (en) Novel compounds and use
ATE141645T1 (de) In vitro-behandlung von fusionsproteinen
WO1998029540A3 (de) REKOMBINANTE FUSIONSPROTEINE AUF DER BASIS RIBOSOMEN-INAKTIVIERENDER PROTEINE DER MISTEL $i(VISCUM ALBUM)
RU95101042A (ru) Рекомбинантный полипептид, антисыворотки, фармацевтическая композиция, способ ингибирования транспорта катионных аминокислот, способ ингибирования продукции окиси азота, способ лечения
EP1191096A4 (de) Neues protein und dessen dns
TW342413B (en) Novel toxins isolated from Bracon Hebetor
ATE103341T1 (de) Antikoerper gegen hochkonservierte aminosaeuresequenzen von immunogenen substanzen, verfahren zur herstellung dieser antikoerper, sowie deren verwendung in immunoassays.
DE3783425D1 (de) Mikroorganismen, die fremdproteinenthaltende pili tragen, isolierte pili, verfahren zur ausscheidung von proteinen in verwendung dieser pili und deren nutzen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049712

Country of ref document: EP